New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots

Masahiro Yasunaga, Shino Manabe, Yasuhiro Matsumura

Research output: Contribution to journalArticlepeer-review

64 Citations (Scopus)


Fibrin clots in non-malignant conditions form only at the onset or during the active stage of disease and disappear within a few weeks as a result of plasmin digestion or replacement with collagen. In contrast, fibrin clot formation and subsequent replacement with collagen in cancer persist for as long as the cancer cells survive in the body. We developed an anti-fibrin chimeric antibody that reacts with fibrin only, and not fibrinogen (the precursor of fibrin), and then attached an anticancer agent (ACA) to the antibody. Thus, the immunoconjugate did not create an immune complex in the blood stream and was selectively accumulated to fibrin clots in the tumor stroma to create a scaffold, from which effective sustained release of the ACA occurred. In a mouse model, the ACA diffused throughout the tumor tissue to damage both tumor cells and vessels, resulting in potent antitumor activity in stroma-rich spontaneous tumors. This new cancer stroma-targeting therapy may result in an increased duration of drug exposure and be a highly effective new therapy, particularly for refractory, stroma-rich cancers.

Original languageEnglish
Pages (from-to)1396-1402
Number of pages7
JournalCancer Science
Issue number7
Publication statusPublished - 2011 Jul


Dive into the research topics of 'New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots'. Together they form a unique fingerprint.

Cite this